| | |||
| PRESS RELEASE |
Regulated Information
Ipsen publishes its
2022 Universal Registration Document
Paris (France), 6 April 2023 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, announced today that its 2022 Universal Registration Document has been filed with the French Autorité des Marchés Financiers on 6 April 2023 and registered under the number D.23-0249.
The document is available on ipsen.com and amf-france.org. Copies will also be available at Ipsen’s headquarters – 65 quai Georges Gorse, 92100 Boulogne-Billancourt, France.
The following documents are incorporated into the 2022 Universal Registration Document:
- Annual Financial Report,
- Board of Directors’ Report on Corporate Governance.
Ipsen
Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience. With total sales of €3.0bn in FY 2022, Ipsen sells medicines in over 100 countries. Alongside its external-innovation strategy, the Company’s research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs: Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen has around 5,000 colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com.
Forward Looking Statement
For further information:
| Investors | |
| Craig Marks Vice President, Investor Relations Tel.: +44 7584 349 193 | |
| Media | |
| Amy Wolf Vice President and Head of Corporate Brand Strategy and Communications Tel.: + 41 79 576 07 23 | Ioana Piscociu Senior Manager, Global Media Relations Tel.: +33 6 69 09 12 96 |
Attachment
